GlassScriptPhysician profile
William J Farrell
NPI 1417951203
$9,784.87
in general payments reported to CMS, 2019-2025
41 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $807 · 2021: $1,089 · 2022: $1,747 · 2023: $1,940 · 2024: $1,530 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,712 · Education: $31.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,712.00 |
| Education | $31.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,032.65 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $854.02 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $757.21 | 2019-2025 | Farxiga, Wainua |
| Pfizer INC. | $634.97 | 2019-2025 | |
| Abbott Laboratories | $560.77 | 2020-2025 | Cardiomems, Jot Dx, Coroflow |
| Novartis Pharmaceuticals Corporation | $505.98 | 2019-2025 | |
| Esperion Therapeutics, INC. | $481.32 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.69 | 2019-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $463.57 | 2022-2023 | Optimizer |
| Novo Nordisk INC | $453.05 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $429.96 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $421.16 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $262.72 | 2019-2023 | |
| Scpharmaceuticals INC. | $237.56 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $211.09 | 2019-2025 | Opsumit, Uptravi |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Farrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.